Iceni™ Pharmaceuticals has a pipeline of ongoing drug development programs:
Cilcane®; cilengitide-based therapy for multiple myeloma. About to enter Phase I/IIa clinical trial.
Novel formulation and delivery technologies, currently at pre-clinical in vivo optimisation studies.
Breast cancer. Iceni Pharmaceuticals has exciting pre-clinical data concerning the efficacy of cilengitide in combination with proteasome inhibitors for the treatment of breast cancer. Further development is underway. Additional independent research has recently also investigated the use of cilengitide as a breast cancer treatment.